Patents by Inventor Edward McDonald
Edward McDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120252797Abstract: Isoxazoles of formula (A) or (B) wherein R1 is a group of formula (IB) The isoxazoles are inhibitors of HSP90 activity, and useful for the treatment of, for example, cancers.Type: ApplicationFiled: June 18, 2012Publication date: October 4, 2012Applicants: Vernalis (Cambridge) Limited, The Institute of Cancer Research, Cancer Research Technology Ltd.Inventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
-
Patent number: 8088761Abstract: Compounds of formula (I), are aurora kinase inhibitors: wherein X is —N—, —CH2-N—, —CH2-CH—, or —CH—; R1 is a radical of formula (IA) wherein Z is —CH2-, —NH—, -0-, —S(O)— —S—, —S(O)2 or a divalent monocyclic carbocyclic or heterocyclic radical having 3-7 ring atoms; Alk is an optionally substituted divalent C1-C6 alkylene radical; A is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring having 5-7 ring atoms; r, s and t are independently 0 or 1, provided that when A is hydrogen then at least one of r and s is 1; R2 is halogen, —CN, —CF3, —OCH3, or cyclopropyl; and R3 is a radical of formula (IB) wherein Q is hydrogen or an optionally substituted phenyl or monocyclic heterocyclic ring with 5 or 6 ring atoms; Z&It;1> is —S—, —S(O)—, —S(O)2-, —O—, —SO2NH—, —NHSO2-, NHC(?O)NH, —NH(C?S)NH—, Or —N(R4)— wherein R4 is hydrogen, C1-C3 alkyl, cycloalkyl, or benzyl; and Alk&It;1> and Alk&It;2> are, independently, optionally substituted divalent C1-C3 alkyleType: GrantFiled: December 21, 2006Date of Patent: January 3, 2012Assignee: Cancer Research Technology LimitedInventors: Vassilios Bavetsias, Edward McDonald, Spyridon Linardopoulos
-
Patent number: 8078313Abstract: Systems and methods for sorting a plurality of unaddressed items may comprise receiving delivery point address data. Furthermore, systems and methods for sorting a plurality of unaddressed items may comprise sorting the plurality of unaddressed items based on the delivery point address data. The plurality of unaddressed items may be sorted in an order in which they are to be delivered within a delivery zone specified by the delivery point address data.Type: GrantFiled: September 30, 2004Date of Patent: December 13, 2011Assignee: United States Postal ServiceInventors: Glenn Edward McDonald, Wilson Wong
-
Publication number: 20110227748Abstract: A system and method for alerting operators of mobile equipment to the presence of people in monitored areas around the periphery of the mobile equipment they are operating is provided. The system includes an RFID detection system which is installed on the mobile equipment and alerts the operator to the presence of people wearing Personal Protection Equipment containing RFID safety tags. The system also includes a tag programming system which allows RFID safety tags to be created. The system also includes a tag testing system which allows a person to test the functionality of the RFID safety tags contained in the personal safety equipment they are wearing. The system also includes RFID personal safety equipment such as 3D safety vests and RFID hardhats which contains RFID safety tags. The 3D safety vests also include enhanced 3D visual markings.Type: ApplicationFiled: March 21, 2011Publication date: September 22, 2011Applicant: MARLEX ENGINEERING INC.Inventors: Uwe D. SCHAIBLE, Jonathan FAVA, Peter Atef Wadie BASL, Norman H. VON STYP-REKOWSKI, Jeff William Edward McDONALD, Jason Philip GARR
-
Publication number: 20110225142Abstract: The present invention provides web site analysis system and method. A crawler is adapted to download data of a target web site and associated with a target web site for security analysis to provide a data set for analysis. A process controller controls a plurality of data analysis processes, each data analysis process associated with one of a plurality of analysis functions related to web site security and integrity, and each data analysis process is adapted to identify data relevant for its associated analysis function from within the data set for analysis. An analyser aggregates the data identified by each of the data analysis processes, and analyses the aggregated data to perform each of the analysis functions to identify indications of any potential security and integrity problems. A report of potential security problems can be automatically generated from the analysed data.Type: ApplicationFiled: March 11, 2011Publication date: September 15, 2011Applicant: MAILGUARD PTY LTDInventor: Craig Edward McDonald
-
Publication number: 20110190297Abstract: The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and/or prevention of cancer.Type: ApplicationFiled: October 6, 2009Publication date: August 4, 2011Inventors: Edward McDonald, Julian Blagg, Mark Pichowicz, Simon Ross Crumpler
-
Patent number: 7946707Abstract: There is disclosed apparatus and method for a test of eye dominance of human subjects for which on each 10-sec trial, one eye starts with a strong image that gets progressively weaker or does not get progressively stronger, while, at the same time, the other eye gets a weak image that gets progressively stronger. The initially strong image will always be seen at the beginning and eventually vision will flip to the other eye's view once that image has achieved sufficient strength to overcome the dominance of the initially strong stimulus (which itself is getting progressively weaker). The subject indicates recognition of the strengthening image and the time is recorded. Results show that the test provides a reliable measure of eye dominance which is seen to vary considerably among people within a sample of normal adults.Type: GrantFiled: February 4, 2010Date of Patent: May 24, 2011Inventors: James Edward McDonald, II, Randolph Blake, Eunice Yang
-
Patent number: 7942068Abstract: In one embodiment, a multi-path ultrasonic flow meter for determining the flow rate of a fluid in a conduit is disclosed comprising at least two transducer pairs attached to the conduit at two chord locations, one greater than and one less than a mid-radius chord, wherein the composite ratio the two path velocities to the flow rate is substantially constant over the range of Reynolds numbers. In another embodiment, a method of determining the flow rate of a fluid in a conduit is disclosed comprising the steps of determining a composite velocity by determining a weighted average of a plurality of path velocities, determining a chord velocity ratio based on the path velocities, determining a profile correction factor based on the composite velocity and the chord velocity ratio, and determining the flow rate based on the composite velocity and the profile correction factor.Type: GrantFiled: March 11, 2009Date of Patent: May 17, 2011Assignee: GE Infrastructure Sensing, Inc.Inventors: Xiaolei Shirley Ao, Robert Caravana, Edward Randall Furlong, Oleg Alexander Khrakovsky, Benjamin Edward McDonald, Nicholas Joseph Mollo, Lydia Shen
-
Publication number: 20100256143Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1 and R2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: April 14, 2008Publication date: October 7, 2010Inventors: Stewart James Baker, Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Joseph Shuttleworth, Elsa Amandine Dechaux, Sussie Lerche Krintel, Stephen Price, Jonathan Martin Large, Edward McDonald
-
Publication number: 20100229654Abstract: In one embodiment, a multi-path ultrasonic flow meter for determining the flow rate of a fluid in a conduit is disclosed comprising at least two transducer pairs attached to the conduit at two chord locations, one greater than and one less than a mid-radius chord, wherein the composite ratio the two path velocities to the flow rate is substantially constant over the range of Reynolds numbers. In another embodiment, a method of determining the flow rate of a fluid in a conduit is disclosed comprising the steps of determining a composite velocity by determining a weighted average of a plurality of path velocities, determining a chord velocity ratio based on the path velocities, determining a profile correction factor based on the composite velocity and the chord velocity ratio, and determining the flow rate based on the composite velocity and the profile correction factor.Type: ApplicationFiled: March 11, 2009Publication date: September 16, 2010Inventors: Xiaolei Shirley Ao, Robert Caravana, Edward Randall Furlong, Oleg Alexander Khrakovsky, Benjamin Edward McDonald, Nicholas Joseph Mollo, Lydia Shen
-
Publication number: 20100210646Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1 and R2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: April 14, 2008Publication date: August 19, 2010Applicants: F. Hoffmann-La Roche AG, The Institute of Cancer Research: Royal Cancer Hos pitalInventors: Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Joseph Shuttleworth, Jonathan Martin Large, Edward McDonald
-
Publication number: 20100179138Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.Type: ApplicationFiled: February 19, 2010Publication date: July 15, 2010Applicants: Vernalis (Cambridge) Limited, Cancer Research Technology Ltd., The Institute Of Cancer ResearchInventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
-
Publication number: 20100137369Abstract: Flowable pharmaceutical depots are described. The flowable pharmaceutical depot includes a polyester, such as a polylactic acid or a poly(trimethylene carbonate) endcapped with a primary alcohol and a pain relieving therapeutic agent, such as a post operative pain relieving therapeutic agent. Method of making and using the same are also described.Type: ApplicationFiled: December 1, 2008Publication date: June 3, 2010Applicant: Medtronic, Inc.Inventors: Michael Eric BENZ, Christopher M. Hobot, Phillip Edward McDonald, Lian Leon Luo, John Kramer
-
Patent number: 7728016Abstract: Compound of a compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity: wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R1 R2 R3 are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor, or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.Type: GrantFiled: June 24, 2004Date of Patent: June 1, 2010Assignees: Vernalis (Cambridge) Limited, Cancer Research Technology Ltd., Institute of Cancer ResearchInventors: Kwai Ming Cheung, Brian William Dymock, Edward McDonald, Martin James Drysdale
-
Publication number: 20100130496Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1, R2, and Y have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: April 14, 2008Publication date: May 27, 2010Applicants: F. Hoffmann-La Roche AG, The Institute of Cancer Research: Royal Cancer HospitalInventors: Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Joseph Shuttleworth, Elsa Amandine Dechaux, Stephen Price, Jonathan Martin Large, Edward McDonald
-
Patent number: 7705027Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: (A), (B) wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO2—, —C(?O)O—, —C(?O)NRA—, —C(?S)NRA—, —SO2NRA—, —NRAC(?O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); andType: GrantFiled: February 9, 2004Date of Patent: April 27, 2010Assignees: Vernalis (Cambridge) Limited, Cancer Research Technology Limited, Institute Of Cancer ResearchInventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
-
Publication number: 20100093769Abstract: The present invention relates to compounds of formula (I) wherein: R1 and R2 are each independently H, alkyl or haloalkyl; R3 and R4 are each independently H, alkyl, haloalkyl or aryl; R5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR9; R7, R8 and each R9 are independently H, alkyl or haloalkyl, wherein at least one of R7, R8 and each R9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.Type: ApplicationFiled: October 5, 2009Publication date: April 15, 2010Applicants: CYCLACEL LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Peter William SHELDRAKE, Butrus ATRASH, Simon GREEN, Edward MCDONALD, Sheelagh FRAME
-
Patent number: 7696204Abstract: Pyrimidines of formula (I): wherein R1 to R4, X and Y are defined in the specification are inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: October 11, 2006Date of Patent: April 13, 2010Assignees: Ludwig Institute for Cancer Research, Cancer Research Technology Limited, The Institute of Cancer Research: Royal Cancer Hospital, Astellas Pharma, Inc., F. Hoffmann-La Roche AGInventors: Edward McDonald, Jonathan M Large, Stephen J Shuttleworth
-
Publication number: 20090325983Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.Type: ApplicationFiled: June 23, 2009Publication date: December 31, 2009Applicants: CYCLACEL LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Peter Martin FISCHER, Michael JARMAN, Edward MCDONALD, Bernard NUTLEY, Florence RAYNAUD, Stuart WILSON, Paul WORKMAN
-
Patent number: D669379Type: GrantFiled: October 24, 2011Date of Patent: October 23, 2012Assignee: General Electric CompanyInventors: Benjamin Edward McDonald, Mykhaylo Barsukov